Similar articles

• [The role of dopaminagonists in the treatment of Parkinson's disease].

  Ransmayr G. Ransmayr G. Praxis (Bern 1994). 2005 Oct 19;94(42):1633-8. doi: 10.1024/0369-8394.94.42.1633. Praxis (Bern 1994). 2005. PMID: 16277084 German.
• Parkinson's disease.

  Clarke C, Moore AP. Clarke C, et al. Clin Evid. 2002 Jun;(7):1208-20. Clin Evid. 2002. Update in: Clin Evid. 2002 Dec;(8):1370-85. PMID: 12230738 Updated. Review. No abstract available.
• Future therapies for Parkinson's disease.

  Hauser RA, Lyons KE. Hauser RA, et al. Neurol Clin. 2004 Oct;22(3 Suppl):S149-66. doi: 10.1016/j.ncl.2004.05.005. Neurol Clin. 2004. PMID: 15501363 Review. No abstract available.
• Parkinson's disease.

  Clarke C, Moore A. Clarke C, et al. Clin Evid. 2002 Dec;(8):1370-85. Clin Evid. 2002. Update in: Clin Evid. 2003 Dec;(10):1582-98. PMID: 12603943 Updated. Review. No abstract available.
• Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.

  Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Hauser RA, et al. Mov Disord. 2000 May;15(3):485-9. Mov Disord. 2000. PMID: 10830413 Clinical Trial.